# Mitoimmune Therapeutics Inc.: Research, Seoul, South Korea

> Mitoimmune Therapeutics Inc.: MitoImmune is a clinical stage biotech company that focuses on developing drugs for diseases in high unmet needs using...

Source: https://millionrounds.com/startup/mitoimmune-therapeutics-inc (Millionrounds; every figure on the page links to its filing or article)

South Korea · [Research startup](https://millionrounds.com/companies)

# Mitoimmune Therapeutics Inc.

MitoImmune is a clinical stage biotech company that focuses on developing drugs for diseases in high unmet needs using mitochondria / ferroptosis based approaches.

Funding reported Last round: Series B

Research Seoul, South Korea

Company summary

- **Founded:** 2018 8 years old
- **Team:** 5 1 to 10 people
- **Funding reported:** 39.5B as listed, currency not stated
- **Last round:** Series B Feb 2021

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Mitoimmune Therapeutics Inc. has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Mitoimmune Therapeutics Inc.

MitoImmune is a clinical stage biotech company that focuses on developing drugs for diseases in high unmet needs using mitochondria / ferroptosis based approaches.

Our molecules based on the MIT platform are basically mitochondria-targeted ferroptosis inhibitors which have been demonstrated to recover intracellular homeostasis of iron, calcium, redox, and immune and to preserve antioxidant systems such as GPX4 under pathological conditions where an abnormal increase of mitochondrial reactive oxygen species (ROS) and the accumulation of calcium and iron accumulation occur.

## What company datasets say Mitoimmune Therapeutics Inc. raised

Funding, as reported

Reported in all **39.5B** in the source's currency

Rounds **2**

Last round **Series B**

Last round size **4.4M**

Last round date **Feb 2021**

Investors listed **10**

## On a portfolio page

Investors who name them

- [IMM Investment](https://millionrounds.com/fund/imm-investment-corp)

Each firm lists Mitoimmune Therapeutics Inc. on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

biotechnology research

Built with from their website

Microsoft Exchange Microsoft 365 Apps & Services Microsoft Exchange Online Nginx Microsoft 365 Outlook Microsoft Email Providers

- **Sector:** Research
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/mitoimmune-therapeutics)

## Research in South Korea

Startups like it

- [**Galux** founded 2020 *Raised*](https://millionrounds.com/company/galux)
- [**ExoCoBio** founded 2017 *Raised*](https://millionrounds.com/company/exocobio)
- [**iN Therapeutics** Yongin-si · founded 2020](https://millionrounds.com/startup/in-therapeutics)
- [**Cyrus Therapeutics** founded 2019](https://millionrounds.com/startup/cyrus-therapeutics)
- [**G+FLAS Life Sciences, Inc.** Seoul · founded 2014](https://millionrounds.com/startup/g-flas-life-sciences-inc)
- [**Dx & Vx** founded 2001](https://millionrounds.com/startup/dx-vx)
- [**Cellmeat** Seoul · founded 2019](https://millionrounds.com/startup/cellmeat)
- [**Bertis Inc** Seongnam-si · founded 2014](https://millionrounds.com/startup/bertis-inc)

## Is this your company?

Add your raise, your deck and your story, and put Mitoimmune Therapeutics Inc. in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)